Dr. Siying Li | Cardiovascular diseases | Best Researcher Award
Dr. Siying Li, Central Hospital affiliated to Shandong First Medical University, China
Dr. Siying Li is an Associate Research Fellow at the Metabolism and Disease Research Center, Central Hospital affiliated with Shandong First Medical University, China. She holds a Ph.D., M.M., and M.B. from Shandong University and has conducted postdoctoral research in cardiometabolic diseases. Her work focuses on hydrogen sulfide regulation in mitochondria, autophagy in heart failure, and ferroptosis in metabolic disorders. With experience as a Visiting Scholar at the University of South Carolina, U.S., she has contributed significantly to medical research. Her findings have been widely recognized, making her a leading researcher in metabolism and cardiovascular health.
AUTHOR PROFILE
🎓 EARLY ACADEMIC PURSUITS:
Dr. Siying Li’s academic journey is marked by excellence and dedication to medical research. She earned her Ph.D. (2010-2015), M.M. (2009-2010), and M.B. (2003-2009) from Shandong University, China, a prestigious institution known for its contributions to medical science. Her strong academic foundation laid the groundwork for her specialization in metabolism and disease research, with a keen focus on cardiometabolic disorders.
💼 PROFESSIONAL ENDEAVORS:
Dr. Li’s career progression reflects her commitment to medical research and academia. She is currently an Associate Research Fellow at the Metabolism and Disease Research Center, Central Hospital affiliated with Shandong First Medical University (2023-Present). Previously, she held key research positions, including:
🔹 Associate Research Fellow at the Shandong Institute of Endocrine and Metabolic Disease (2021-2023)
🔹 Assistant Research Fellow at the Department of Pathophysiology, School of Basic Medicine, Shandong University (2017-2020)
🔹 Postdoctoral Researcher at Shandong University (2015-2017)
🔹 Visiting Scholar at the University of South Carolina, U.S. (2011-2013)
Her extensive experience in both national and international institutions has provided her with a global perspective on medical research, fostering interdisciplinary collaborations.
🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR DISEASES:
Dr. Li’s research is centered on cardiometabolic diseases, an area of growing significance in modern medicine. Her key research contributions include:
✅ Hydrogen Sulfide & Mitochondria in Heart Failure – Investigating its regulatory role in cellular metabolism and autophagy.
✅ Iron Metabolism & Ferroptosis in Cardiometabolic Diseases – Exploring its potential in disease progression and therapeutic interventions.
Her work has advanced the understanding of molecular mechanisms in cardiovascular health, paving the way for potential breakthroughs in medical treatments.
🌍 IMPACT AND INFLUENCE:
Dr. Li’s research has made a significant impact on the global scientific community, particularly in the fields of metabolism, endocrinology, and cardiovascular health. Her studies on ferroptosis and hydrogen sulfide regulation have influenced new treatment approaches for heart failure and metabolic disorders. Her collaborations with leading research institutions and hospitals have further amplified the clinical relevance of her findings.
📚 ACADEMIC CITATIONS AND RECOGNITION:
Dr. Li’s work has been widely recognized in peer-reviewed journals and international conferences. Her research has garnered numerous citations, reflecting its significance and contribution to the medical field. She has also actively participated in academic symposiums and medical panels, sharing her insights with researchers worldwide.
🚀 LEGACY AND FUTURE CONTRIBUTIONS:
Dr. Li’s ongoing research promises to make groundbreaking contributions to medicine. Her expertise in molecular metabolism and cardiovascular pathophysiology positions her as a key figure in the future of personalized medicine and targeted therapies. Her dedication to advancing scientific knowledge and mentoring young researchers ensures a lasting impact on the field of medical science.
🏅 CONCLUSION:
Dr. Siying Li is a distinguished researcher whose contributions to cardiometabolic diseases have significantly advanced medical science. Her expertise in hydrogen sulfide regulation, mitochondrial function, and ferroptosis has provided valuable insights into heart failure and metabolic disorders. With a strong academic background, extensive research experience, and international collaborations, she has established herself as a leading scientist in her field. Her work not only enhances fundamental understanding but also paves the way for innovative therapeutic approaches.
TOP NOTABLE PUBLICATIONS
The potential role of hydrogen sulfide in regulating macrophage phenotypic changes via PINK1/parkin-mediated mitophagy in sepsis-related cardiorenal syndrome
Authors: Chen, Y., Cao, W., Li, B., … Yang, G., Li, S.
Journal: Immunopharmacology and Immunotoxicology
Year: 2024
Cyclophilin D as a potential therapeutic target of liver ischemia/reperfusion injury by mediating crosstalk between apoptosis and autophagy
Authors: Yang, M., Wang, Z., Xie, J., … Li, S., Song, Y.
Journal: Chronic Diseases and Translational Medicine
Year: 2023
Urine proteomics for profiling of mouse toxoplasmosis using liquid chromatography tandem mass spectrometry analysis
Authors: Cui, L.-L., Zhou, C.-X., Han, B., … Xie, S.-C., Zhou, D.-H.
Journal: Parasites and Vectors
Year: 2021
S-allylmercaptocysteine ameliorates lipopolysaccharide-induced acute lung injury in mice by inhibiting inflammation and oxidative stress via nuclear factor kappa B and Keap1/Nrf2 pathways
Authors: Mo, M., Li, S., Dong, Z., … Li, A., Zhao, Z.
Journal: International Immunopharmacology
Year: 2020
The key role of macrophage depolarization in the treatment of COPD with ergosterol both in vitro and in vivo
Authors: Sun, X., Liu, Y., Feng, X., … Li, S., Zhao, Z.
Journal: International Immunopharmacology
Year: 2020
S-allylmercaptocysteine targets NRF2 in osteoarthritis treatment through NOX4/NF-ΚB pathway
Authors: Yang, G., Sun, S., Wang, J., … Yuan, L., Li, S.
Journal: Drug Design, Development and Therapy
Year: 2020
A nucleoside/nucleobase-rich extract from Cordyceps sinensis inhibits the epithelial-mesenchymal transition and protects against renal fibrosis in diabetic nephropathy
Authors: Dong, Z., Sun, Y., Wei, G., Li, S., Zhao, Z.
Journal: Molecules
Year: 2019
Ergosterol attenuates cigarette smoke extract-induced COPD by modulating inflammation, oxidative stress and apoptosis in vitro and in vivo
Authors: Sun, X., Feng, X., Zheng, D., … Li, S., Zhao, Z.
Journal: Clinical Science
Year: 2019
Yifei tongluo, a Chinese herbal formula, suppresses tumor growth and metastasis and exerts immunomodulatory effects in Lewis lung carcinoma mice
Authors: Qi, Q., Hou, Y., Li, A., … Li, S., Zhao, Z.
Journal: Molecules
Year: 2019
Ergosterol ameliorates diabetic nephropathy by attenuating mesangial cell proliferation and extracellular matrix deposition via the TGF-β1/Smad2 signaling pathway
Authors: Dong, Z., Sun, Y., Wei, G., Li, S., Zhao, Z.
Journal: Nutrients
Year: 2019